arrow
A

Alicia López-Abad

Hospital Virgen de la Arrixaca
H指数:8
被引数:843

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Variable-Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation

基于临床变量的机器学习预测早期mCRPC:开发及多中心外部验证

2026-07-020
PRE
PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?

前列腺特异性抗原(PSA)反应预测转移性激素敏感前列腺癌(mHSPC)患者进展的时机:何时为最佳时间点?

2026-01-010
PRE
Bone Health in Metastatic Hormone-Sensitive Prostate Cancer: Where We Stand and Where We Can Improve

转移性激素敏感性前列腺癌的骨骼健康:我们目前的进展及可改进之处

2025-12-130
OAAI
HLA class-I genotyping to personalize Bacille Calmette–Guerin immunotherapy in bladder cancer

HLA class-I基因分型用于个性化膀胱癌的Bacille Calmette–Guerin免疫疗法

2025-12-120
OAAI
Comparison of short versus long stent duration on outcomes after pediatric kidney transplantation: A systematic review by the Young Academic Urologists Pediatric Urology and Kidney Transplantation Working Groups

短与长支架置入时间对儿童肾移植后结局的比较:由青年学术泌尿外科医师儿科泌尿与肾移植工作组完成的系统综述

2025-10-011
PRE
Interplay of KIR2DL5; nitric oxide; and tobacco smoking in predisposition to bladder cancer

KIR2DL5、一氧化氮和吸烟在膀胱癌易感性中的相互作用

2025-09-040
OA
Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with M. bovis BCG or Other Therapies
2025-01-100
OAAI
Exploring the Immunoresponse in Bladder Cancer Immunotherapy
CELLS
IF5.2
2024-11-221
OAAI
Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study

接受阿帕鲁胺治疗的转移性激素敏感性前列腺癌 (mHSPC) 患者的超低前列腺特异性抗原 (PSA) 水平和改善的肿瘤学结局: 一项真实世界的多中心研究

2024-10-180
OAAI